Vitamin D: Who Actually Needs to Supplement — and Who's Wasting Their Money

How we sourced this. Every claim below is tied to a named study — a meta-analysis, a clinical practice guideline, or the live trial registry — and linked. We also graded the evidence: where it’s strong, we say so; where it’s early or thin, we say that too. This piece carries a real byline and was reviewed for accuracy before publishing, because on health topics a citation you can’t stand behind is worse than no citation at all. Last updated 17 August 2026.

The supplement everyone takes and almost nobody has questioned

Vitamin D occupies a strange spot in the gym. It’s the one supplement clients take without being asked to, usually at a dose someone picked off a shelf, usually forever. Nobody argues about it the way they argue about creatine. Which is exactly why it’s worth an evidence page.

Here’s the thesis, and it’s the thing most coaches get backwards: vitamin D is a correction supplement, not a performance supplement. If a client is genuinely low, topping them up does something. If they’re already sufficient, the evidence that more helps ranges from thin to nonexistent — and at high enough doses it starts working against them.

That’s a more useful thing to know than “vitamin D is good for you,” and it changes what you actually say on the gym floor.

What the evidence says about strength (this is the part that surprises people)

If you’ve seen vitamin D marketed as a performance supplement, the meta-analysis does not back it. A 2019 pooled analysis of 8 randomised trials in 284 athletes found no effect on overall muscle strength — SMD 0.05 (95% CI −0.39 to 0.48, p = 0.84).³ Muscle power measured by vertical jump: also nothing.

The nuance is where it gets coach-useful. In subgroup analysis, lower-limb strength did improve (SMD 0.55), and the effect was larger in athletes who trained indoors (SMD 0.48) — the group most likely to have been low to begin with.³ A 2023 meta-analysis of 11 trials in 436 athletes reached the same overall verdict: no statistically significant effect on maximal strength or power, and it explicitly split its analysis by whether participants started above or below 75 nmol/L.⁴

Read those two together and the picture is consistent: you are not adding strength to a sufficient athlete. You may be removing a handicap from a deficient one.

Evidence grade: moderate, and the direction matters more than the size. Multiple meta-analyses agree there’s no general strength benefit; the signal lives in correcting deficiency.

So who actually is low?

This is the part worth memorising, because it’s how you avoid recommending a supplement to someone who doesn’t need it.

Across 14 standardised European population studies (n = 55,844), 17.7% of people fell below 30 nmol/L during the extended winter — October to March — versus 8.3% in summer.² Using the looser 50 nmol/L threshold, the annual figure was 40.4%. If you coach in Berlin, Munich, or anywhere north of the Alps, winter is not a hypothetical.

In elite athletes specifically, pooled prevalence of insufficiency (below 50 nmol/L) was 30% in adults across 51 studies and 5,456 participants — and the authors call that a conservative estimate, because winter studies were under-represented.¹ Earlier work across 23 studies and 2,313 athletes found risk significantly elevated for winter and spring (RR 1.85), for indoor sport (RR 1.19), and at higher latitudes.¹⁶

The practical risk list for a coach: trains indoors, October through March, higher latitude, darker skin, covered clothing, or almost never outdoors in daylight. If none of those apply to your client, the case for supplementing weakens considerably.

Evidence grade: strong. Large, standardised, consistent across regions.

What it does not do

Fractures

This is the one that will surprise clients most, because “vitamin D for bones” is practically folk wisdom. A 2026 BMJ systematic review of 69 trials and 153,902 participants found little to no effect of vitamin D on fracture risk: risk ratio 1.00 (95% CI 0.95–1.06) across 36 trials and 92,045 participants — with GRADE certainty rated high.⁶ Calcium alone and the combination fared no better on the outcomes the authors considered clinically meaningful.

High certainty is rare in nutrition science. When you get it, you use it.

Evidence grade: strong (for the absence of an effect).

Falls — with an important exception

Falls are messier and worth splitting. A 2024 network meta-analysis of 35 trials and 58,937 participants found 800–1000 IU/day reduced fall risk (RR 0.85) versus placebo — but that the benefit was concentrated in people whose baseline 25(OH)D was at or below 50 nmol/L (RR 0.69), and absent above it. Crucially, doses above 1000 IU/day increased fall risk compared with 800–1000 IU/day, and intermittent dosing showed no preventive effect at all.⁷ A separate meta-analysis of 15 trials found intermittent or single high-dose regimens prevented neither falls (RR 1.03) nor fractures (RR 0.99), and may even raise fall risk.¹⁷

Same pattern as strength: it’s correction, not enhancement, and the dose-response is not a straight line upward.

Evidence grade: moderate. The BMJ review above found little to no fall benefit overall; the network meta-analysis finds it in the deficient subgroup. Honest coaching means saying both.

Stress fractures

A 2026 meta-analysis of 15 studies and 4,183 participants found people with stress fractures had lower vitamin D levels (mean difference −5.82 nmol/L), but the association was significant in military personnel and male participants — and not in the athlete or female subgroups analysed separately.¹² That’s an association, not a demonstrated cause, and the athlete-specific case is not yet made.

Evidence grade: early. Interesting, not actionable as a promise.

The immune claim, honestly

Clients will bring this one up every winter. The strongest version of it is real but small.

A 2021 meta-analysis of 43 studies and 48,488 participants found vitamin D reduced the odds of having at least one acute respiratory infection — OR 0.92 (95% CI 0.86–0.99).⁸ The effect was clearer in the subgroups that got daily doses of 400–1000 IU (OR 0.70) rather than large intermittent boluses. The earlier individual-participant-data analysis found the same shape, with the biggest benefit in people starting below 25 nmol/L (adjusted OR 0.30) and essentially none in those given bolus doses.^9, 8

So: a modest, daily-dosing effect that is largest in the very deficient. That is a legitimate thing to mention. “It’ll stop you getting sick” is not.

Evidence grade: moderate for a small effect; strong for the finding that daily beats bolus.

More is not better — and this is the part coaches skip

The over-supplementation trap is the real story here, and it’s under-discussed because vitamin D has a reputation for being harmless.

Across 22 trials and 12,952 participants lasting six months or more, daily doses of 3200–4000 IU raised the relative risk of hypercalcaemia to 2.21 (95% CI 1.26–3.87), with risks of falls (RR 1.25) and hospitalisation (RR 1.16) also elevated. The authors’ conclusion is blunt: this dose “is not completely safe.”¹⁰

A three-year randomised trial comparing 400, 4000 and 10,000 IU/day in 373 healthy adults adds the texture: serious problems were rare, but hypercalciuria occurred in 31% of the 10,000 IU group versus 17% at 400 IU, and mild hypercalcaemia in 9% versus 0%.¹¹ No dramatic harm — but no benefit either, and a clear dose-dependent drift in the wrong direction.

Then there’s the guideline that ties it together. The Endocrine Society’s 2024 clinical practice guideline suggests against empiric vitamin D supplementation above the reference intake to lower disease risk in healthy adults under 75, and against routine 25(OH)D screening in the general population — including in people with obesity or darker skin — because no trial evidence supports it. For people over 50 who do have an indication, it recommends daily dosing rather than intermittent high doses.⁵ (According to PubMed: Demay et al., J Clin Endocrinol Metab 2024, DOI 10.1210/clinem/dgae290.)

Evidence grade: strong. A guideline built on GRADE-assessed systematic review, plus consistent RCT safety data.

The client on 5,000 IU

You will meet this person. They read something, they bought the big bottle, they’ve been on it for two years, and they feel fine.

You are not their doctor and you don’t get to tell them to stop. What you can do is give them the information and point them to someone who can act on it: the everyday evidence supports modest daily dosing, the guideline explicitly advises against empiric high-dose supplementation in healthy adults under 75, and the safety signal starts appearing in the 3200–4000 IU range. If they want to know their actual level, that’s a conversation with a doctor — who can also check whether anything else is going on. Medical conditions, pregnancy, kidney disease, and anything involving prescribed medication all belong with a professional, full stop.

That referral is not a failure of expertise. It’s the thing that makes the rest of your advice trustworthy.

What’s about to be proven

Here’s what a static supplement page can’t give you: the live edge. The clinical registry currently lists 288 vitamin D trials recruiting or about to start.¹³ Two of them should be on your radar.

Vitamin D during GLP-1 weight-loss treatment. A Vanderbilt trial is testing calcium-HMB plus vitamin D3 against placebo in older adults starting semaglutide, specifically targeting the muscle loss that comes with rapid medication-driven weight loss.¹⁴ Your clients are already on these drugs. Nobody can claim vitamin D protects muscle during GLP-1 use — but the coach who understands the question before the answer arrives is the coach clients trust when it lands.

Vitamin D and quadriceps recovery after ACL reconstruction. A phase 2 randomised trial in Hong Kong is testing whether vitamin D3 improves quadriceps strength post-ACL — a question every coach who has taken a client through that rehab has quietly wondered about.¹⁵

Beyond those, the registry is thick with trials in older adults, muscle function, and frailty. We’ll update this piece as they read out — that’s the point of an evidence page that’s alive instead of frozen.

Your script for Monday

When the next client asks, here’s the whole thing in plain language:

“Vitamin D isn’t a performance supplement — the studies in athletes don’t show it makes you stronger. What it does is fix a shortfall, and if you train indoors through a northern winter there’s a real chance you’ve got one. A modest daily dose through the dark months is sensible and cheap. Don’t take a mega-dose and don’t do the once-a-month megapill thing — the research says daily beats big, and the very high doses start showing side effects without showing benefits. If you actually want to know your level, ask your doctor. That’s their test, not mine.”

That’s it. No hedging, no fear-selling, no overpromising. Just the evidence, translated into something a human can act on — which is the entire job.

Sqwod reads the research so your clients don’t have to. This is coaching information, not medical advice; anything involving a medical condition, pregnancy, kidney disease, or medication belongs with a qualified professional, as does any blood test. Spotted something that needs sharpening? That’s how an evidence page stays honest — tell us and we’ll correct it in public.